Karyopharm Q2 Loss Widens to $67M; Cash Runway Only Into September
KPTI sits 16% above its 52-week low of $1.8.
Summary
Karyopharm's Q2 results show a widening loss and a cash runway that ends in September, forcing the company to seek financing or strategic alternatives.
Key Events · Earnings and Guidance · KPTI
-
Q2 Net Loss Widens to $67M
Net loss of $67.0 million, or $2.32 per share, compared to $37.3 million in Q2 2025. The increase was driven by a $32.1 million non-cash charge from fair value remeasurement of warrants and embedded derivatives.
-
Cash Runway Only Into September
Cash, cash equivalents, and investments totaled $65.4 million as of June 30, 2026. The company expects this to fund operations only into September 2026, with a $15.8 million principal payment due September 10, 2026 under its senior secured term loan.
-
Liquidity Covenant Breach Risk
If the September 10 payment is made without additional financing or a lender waiver, cash would fall below the $10.0 million minimum liquidity covenant, triggering an event of default.
-
Financing and Strategic Alternatives Underway
The company is working with Centerview Partners to evaluate financing opportunities and strategic alternatives to extend its cash runway and maximize shareholder value.
Analysis · KPTI · Life Sciences
A widening Q2 net loss of $67.0 million was driven by a $32.1 million non-cash charge from warrant and derivative remeasurement. More critically, the company disclosed that its cash runway extends only into September 2026, with a $15.8 million debt payment due September 10 that could breach its minimum liquidity covenant. The company is actively exploring financing and strategic alternatives, making this a pivotal moment for shareholders.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.8% of the 985 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46M. The 52-week trading range was $1.80 to $10.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.